Divalproex Sodium Tablet, Extended Release
Product Images NDC 72789-286

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 72789-286). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789286 Label (72789286)

Label for Divalproex sodium extended-release tablets, 250 mg strength, containing 60 tablets. The label includes the NDC 72789-286-60 and is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. It also features dosage instructions, warnings about drowsiness, and storage instructions, along with lot number K22C87 and expiration date 04/2024.*

FDA Label Image

Image 1 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 01)

Chemical structure of divalproex sodium, showing its molecular components including sodium ions and valproate moieties in a polymeric form.*

FDA Label Image

Image 2 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 02)

A cumulative distribution plot depicting the percentage reduction in CPS rate in patients treated with Divalproex Sodium Delayed-Release tablets compared to a placebo. The x-axis shows the percentage of patients, while the y-axis indicates improvement or worsening in CPS rate. The solid line represents Divalproex Sodium delayed-release, and the dashed line represents placebo.*

FDA Label Image

Image 3 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 03)

A Kaplan-Meier curve chart depicting the percentage reduction in CPS rate versus the percentage of patients for two groups: high dose Divalproex Sodium Delayed Release (solid line) and low dose Divalproex Sodium Delayed Release (dashed line). The vertical axis ranges from -100% worsening to 100% improvement in CPS rate, with a horizontal line at zero indicating no change. The horizontal axis represents the percentage of patients from 0 to 100%.*

FDA Label Image

Image 4 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 04)

A bar graph comparing the effect of Divalproex Sodium Extended-Release Tablets versus placebo. The y-axis measures an unspecified variable, with Divalproex showing a value of 1.2 and placebo a value of 0.6, indicating a difference marked as statistically significant (p=0.006).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.